Appropriate use criteria

AAOS Comments on Proposed Medicare Payment Policy Changes for 2024

Retrieved on: 
Monday, September 18, 2023
ASC, IPO, Healthcare Common Procedure Coding System, Surgeon, CMS, Report, American Academy of Orthopaedic Surgeons, CPT, Centers for Medicare & Medicaid Services, PRO, MBA, Medicare, Appropriate use criteria, Work, MD, Patient, Physician, MPFS, HCPCS, AAOS, Hospital, Health insurance, Nursing

WASHINGTON, Sept. 18, 2023 /PRNewswire/ -- The American Association of Orthopaedic Surgeons (AAOS) issued formal comments to the Centers for Medicare & Medicaid Services (CMS) on the agency's proposed payment policy changes in the Medicare program for Calendar Year (CY) 2024.

Key Points: 
  • WASHINGTON, Sept. 18, 2023 /PRNewswire/ -- The American Association of Orthopaedic Surgeons (AAOS) issued formal comments to the Centers for Medicare & Medicaid Services (CMS) on the agency's proposed payment policy changes in the Medicare program for Calendar Year (CY) 2024.
  • The AAOS' concerns center around ongoing cuts to physician reimbursement, as the CY 2024 Medicare Physician Fee Schedule (MPFS) proposed rule includes a $32.75 conversion factor, which is a $1.14 (almost 3.26%) decrease from the $33.89 conversion factor for 2023.
  • "AAOS is committed to helping create an equitable healthcare system for patients and physicians," said AAOS President Kevin J. Bozic, MD, MBA, FAAOS.
  • "Therefore, we urge CMS to support a statutory fix that provides an annual inflationary update for physicians, akin to all other providers covered by the Medicare payment system.

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Retrieved on: 
Wednesday, May 24, 2023
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, GE HealthCare, Fluoroestradiol F-18, ER, Society of Nuclear Medicine and Molecular Imaging, Society, Surgeon, University, SNMMI, Education, CDK, Molecular imaging, University of Washington, Policy, FES, GE, PET, University of Pennsylvania, Prognosis, Multimedia, Research, Medicine, Biomarker, NCCN, Appropriate use criteria, Professor, Patient, MBC, Physician, Diagnosis, Neoplasm, Fred Hutchinson Cancer Research Center, FDA, Breast cancer, Cardiology, Neurology, Biopsy, FDG, Medical imaging

GE HealthCare’s Cerianna, available in the U.S., is the only FDA approved FES PET imaging agent.

Key Points: 
  • GE HealthCare’s Cerianna, available in the U.S., is the only FDA approved FES PET imaging agent.
  • This inclusion in the NCCN Guidelines comes after the Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently published Appropriate Use Criteria to guide referring and imaging physicians in appropriate use of estrogen receptor (ER)-targeted PET imaging with 16α-18F-fluoro-17ß Fluoroestradiol.
  • View the full release here: https://www.businesswire.com/news/home/20230524005415/en/
    FES PET is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (Graphic: Business Wire)
    In the U.S., it is estimated that 181,0002 people have metastatic breast cancer (also called stage 4)3, with a five-year survival rate of 28 percent4.
  • The NCCN Guidelines are the recognized standard for clinical direction and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine.

Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022

Retrieved on: 
Friday, September 16, 2022
PVD, Safety, Journal, Efficiency, Beth Israel Deaconess Medical Center, Research, PHG, Patient, Physician, Technology, Cardiology, Control, Philips, Aortic valve, Electrophysiology, 2D, Revascularization, Instant, Pilot in command, American College, 3D, Assistant, Sale, Journal of Comparative Effectiveness Research, List of Dove Medical Press academic journals, Interventional cardiology, Treatment, PCI, Decision-making, Guideline, NYSE, MD, Association, EPIQ, Length of stay, Physiology, AEX, SAS, ISR, Moyamoya disease, ESC, Appropriate use criteria, Veni, vidi, vici, Workflow, Health, TAVR, Calendar, Journal of the American College of Cardiology, Solution, General manager, Telemetry, Harvard Medical School, JACC, MCOT, IVUS, TCT, Medical imaging, Medicine, Medical device, Silviculture, Medicine

In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.

Key Points: 
  • In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.
  • At Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve.
  • Visitors to TCT 2022 will have access to Philips latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions.
  • Visit the Philips Engagement Hub to experience innovative cardiac solutions and follow the #TCT2022 conversation on @PhilipsLiveFrom throughout the event.

Revenue Cycle Coding Strategies and First Healthcare Compliance Offer Revenue Cycle and Compliance Summit with Expert Speakers on June 23, 2022

Retrieved on: 
Thursday, May 12, 2022
Education, AUC, CLE, Solution, Appropriate use criteria, Credentialing, EST, Practice management software, OSHA, RCCS, Compliance, Program, Hospital, Credit, HIPAA, Government, Medicine, Communications satellite

WILMINGTON, Del., May 12, 2022 /PRNewswire-PRWeb/ -- Revenue Cycle Coding Strategies (RCCS) and First Healthcare Compliance to provide resources for professionals facing the challenges of auditing, billing, and coding compliance. The virtual half-day online educational event will be held on June 23, 2022, from 12:00 p.m. EST until 4:30 p.m. EST and registration is open to the public.

Key Points: 
  • Revenue Cycle Coding Strategies (RCCS) and First Healthcare Compliance to provide resources for professionals facing the challenges of auditing, billing, and coding compliance.
  • WILMINGTON, Del., May 12, 2022 /PRNewswire-PRWeb/ -- Revenue Cycle Coding Strategies (RCCS) and First Healthcare Compliance to provide resources for professionals facing the challenges of auditing, billing, and coding compliance.
  • "During this time of continuous change, quality education about compliance related to the revenue cycle is imperative", states Julie Sheppard, Founder and President of First Healthcare Compliance.
  • About Revenue Cycle Coding Strategies : Revenue Cycle Coding Strategies is a trusted partner of private practices, healthcare systems, hospitals, and other industry stakeholders, providing solutions for challenges in all aspects of the charge capture process.

Konica Minolta Healthcare Highlights Automated Features in Exa Platform that Enhance Productivity at Annual HIMSS Meeting

Retrieved on: 
Monday, March 14, 2022
RIS, Insurance, Center, Healthcare Information and Management Systems Society, GLOBE, Enterprise, Health care, PACS, Clinical decision support system, Enterprise imaging, Database, Konica Minolta, AUC, College of Healthcare Information Management Executives, HIMSS, Medicaid, Appropriate use criteria, Efficiency, CMS, Hospital, Health insurance, Billing

WAYNE, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- At the annual meeting of the Healthcare Information and Management Systems Society (HIMSS), Konica Minolta Healthcare Americas, Inc., is highlighting new features of the Exa Platform that automate common clinical and administrative tasks, enabling radiology departments and practices to enhance staff productivity, improve reimbursement and capture non-covered costs.

Key Points: 
  • WAYNE, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- At the annual meeting of the Healthcare Information and Management Systems Society (HIMSS), Konica Minolta Healthcare Americas, Inc., is highlighting new features of the Exa Platform that automate common clinical and administrative tasks, enabling radiology departments and practices to enhance staff productivity, improve reimbursement and capture non-covered costs.
  • About Konica Minolta Healthcare Americas, Inc.
    Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology.
  • Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902).
  • For more information on Konica Minolta Healthcare Americas, Inc., please visit https://healthcare.konicaminolta.us

Canon Medical and Resoundant, Inc. Partnership to Provide Magnetic Resonance Elastography on Canon MRI Scanners

Retrieved on: 
Tuesday, November 30, 2021
Radiology, Health, Medical Devices, Patient, Mayo Clinic, American College of Radiology, Heart, Mayo Foundation for Medical Education & Research v. United States, CEO, Safety, Technology, Noise, AI, General manager, AICE, Health care, ReSound, Google Images, NAFLD, Fatty liver disease, MD, Diagnosis, Canon Medical Systems Corporation, Health, Radiology, Appropriate use criteria, Solution, MRE, Magnetic resonance elastography, Trust, Cirrhosis, Research, Non-alcoholic fatty liver disease, Medical education, Ministry of Education (Malaysia), MRI, American College, NASH, CT, Medical research, Nuclear medicine, Life, Blanche, Quality of life, Medical imaging, MRE, Resoundant, Canon Medical Systems, MRE, RESOUNDANT, CANON MEDICAL SYSTEMS

Canon Medical Systems Corporation and Resoundant, Inc. (Rochester, MN, USA) have signed a licensing agreement for the purpose of incorporating the advanced Magnetic Resonance Elastography (MRE), developed by Resoundant on the Canon MRI platforms.

Key Points: 
  • Canon Medical Systems Corporation and Resoundant, Inc. (Rochester, MN, USA) have signed a licensing agreement for the purpose of incorporating the advanced Magnetic Resonance Elastography (MRE), developed by Resoundant on the Canon MRI platforms.
  • Canon Medical and Resoundant have been working closely together to implement a seamless integration of the latest MRE technology on Canons newest line of MRI scanners.
  • MR Elastography was invented at Mayo Clinic and is the only MRI technology that has been validated for staging liver fibrosis.
  • Resoundant, Inc. is a medical technology company dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance Elastography (MRE) available around the world.

New Exa Platform Functionality Automates Decision Support, Insurance-Related Tasks for Enhanced Productivity and Profitability

Retrieved on: 
Tuesday, November 23, 2021
Insurance, Radiological Society of North America, RSNA, Health care, Workflow, Solution, Clinical decision support system, Appropriate use criteria, CMS, GLOBE, Health, Medicaid, Konica Minolta, Efficiency, AUC, RIS, PACS, Center, Health insurance

WAYNE, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., announced today new features and functionality for the Exa Platform that automate common clinical and administrative tasks.

Key Points: 
  • WAYNE, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., announced today new features and functionality for the Exa Platform that automate common clinical and administrative tasks.
  • Together, these capabilities will enable radiology departments and imaging centers to increase revenue and profitability by improving reimbursement and capture non-covered costs.
  • Konica Minolta will showcase these new solutions for the Exa Platform, which includes RIS, PACS and Billing, at the 2021 annual meeting of the Radiological Society of North America (RSNA).
  • As important, these latest features further expand the zero footprint, digital Exa Platform experience for our customers, from patient check-in to scheduling, ordering and billing.

Voya expands suite of target date solutions for retirement plan participants with launch of MyCompass American Funds

Retrieved on: 
Tuesday, November 9, 2021
Professional Services, Other Professional Services, Human Resources, Finance, Consulting, Banking, Family, Appropriate use criteria, Fortune 500, Ethisphere Institute, Industry, TDF, Behavior, Health, Retirement, Employee Benefit Research Institute, No, Knowledge, Longevity, Voya Financial, VOYA, Great Places, Disability, Popularity, Database, LinkedIn, Solution, Workplace, NYSE, CIT, Capital Group Companies, EBRI, Risk, Bloomberg, Financial adviser, Bank, Financial services, Risk management

Voya Financial, Inc. (NYSE: VOYA), announced today the launch of MyCompass American Funds, the latest addition to Voyas suite of target date fund (TDF) solutions for plan sponsors.

Key Points: 
  • Voya Financial, Inc. (NYSE: VOYA), announced today the launch of MyCompass American Funds, the latest addition to Voyas suite of target date fund (TDF) solutions for plan sponsors.
  • Now available to all Voya retirement plan customers, MyCompass American Funds offers a collective investment trust (CIT) target date series that includes management from industry leaders including Voya Investment Management (IM), American Funds from Capital Group and Wilmington Trust Co.
  • The new target date series further complements Voyas current suite of TDF solutions including MyCompass Index and those offered through Voya IM.
  • Innovative solutions, including those such as MyCompass American Funds target date series, provide greater opportunity for plan sponsors and advisors to help individuals on their retirement planning journey.

MedCurrent's Radiology Clinical Decision Support Solutions Now Available on Epic's App Orchard

Retrieved on: 
Monday, October 11, 2021
Center, AUC, Program, PAMA, Journal of the National Comprehensive Cancer Network, Royal, Social Security Amendments of 1965, Protecting Access to Medicare Act of 2014, Collection, Radiology, IH, ACC, NCCN, Health, CMS, National Comprehensive Cancer Network, Medicare, COO, EHR, Health care, Intermountain Healthcare, Appropriate use criteria, Centers for Medicare & Medicaid Services, CDS, Solution, Compliance, Center for Medicare and Medicaid Innovation, Royal college, Patient, American College, RCR, Epic Systems, Medical imaging

TORONTO, Oct. 11, 2021 /PRNewswire-PRWeb/ --MedCurrent, a global leader in radiology Clinical Decision Support (CDS) software solutions, today announced a new integration with Epic's EHR to provide clinicians with access to evidence-based guidelines at the point of care.

Key Points: 
  • TORONTO, Oct. 11, 2021 /PRNewswire-PRWeb/ --MedCurrent, a global leader in radiology Clinical Decision Support (CDS) software solutions, today announced a new integration with Epic's EHR to provide clinicians with access to evidence-based guidelines at the point of care.
  • In the US market, OrderWise is a qualified Clinical Decision Support Mechanism (CDSM) by the Centers for Medicare and Medicaid Services (CMS) that guides clinicians through clinical decision pathways to help them order the most appropriate diagnostic imaging tests for their patients directly at the point of care.
  • Find MedCurrent in Epic's App Orchard here: https://apporchard.epic.com/gallery?id=10304
    MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on improving the quality of care and managing health system costs through our innovative and scalable solutions, OrderWise and iRefer CDS.
  • For more information, visit http://www.medcurrent.com
    Epic and App Orchard are registered trademarks of Epic Systems Corporation.

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Retrieved on: 
Tuesday, September 21, 2021
AUA, News, UCLA, PET, Man, American Urological Association, Diagnosis, NCCN, Recurrence, CT, Medicare, Patient, TGA, Physician, Journal of the National Comprehensive Cancer Network, PSA, AUC, LinkedIn, American College, Degenerative disease, SNMMI, Society of Nuclear Medicine and Molecular Imaging, GLOBE, US Foods, Prostate cancer, ASCO, Company, Australian Securities Exchange, ASX, Molecular imaging, American Society of Clinical Oncology, Radiopharmaceutical, Appropriate use criteria, Radiology, PSMA, MTR, Society, TLX, Medical imaging

It follows updated guidance from the National Comprehensive Cancer Network (NCCN)1, which recognises the increased sensitivity and specificity of PSMA PET tracers, compared to conventional imaging for detecting micrometastatic disease, at both initial staging and biochemical recurrence.

Key Points: 
  • It follows updated guidance from the National Comprehensive Cancer Network (NCCN)1, which recognises the increased sensitivity and specificity of PSMA PET tracers, compared to conventional imaging for detecting micrometastatic disease, at both initial staging and biochemical recurrence.
  • The systematic review2 also noted:
    PSMA PET may have additional use in selecting patients for PSMA directed therapy and assessing response to therapies.
  • PSMA PET radiotracers, similar to other radiopharmaceuticals, have an excellent safety profile, given the sub-pharmacological mass dose and high specific activity administered.
  • Access to PSMA PET will be widely available and this game-changer technology will ultimately become part of the routine staging of prostate cancer patients.